- Home
- NA vs SAVA Comparison
NA vs SAVA Comparison
Compare NA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- SAVA
- Stock Information
- Founded
- NA 2019
- SAVA 1998
- Country
- NA China
- SAVA United States
- Employees
- NA N/A
- SAVA N/A
- Industry
- NA Semiconductors
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- NA Technology
- SAVA Health Care
- Exchange
- NA Nasdaq
- SAVA Nasdaq
- Market Cap
- NA 77.6M
- SAVA 70.5M
- IPO Year
- NA 2022
- SAVA N/A
- Fundamental
- Price
- NA $5.94
- SAVA $2.12
- Analyst Decision
- NA
- SAVA Buy
- Analyst Count
- NA 0
- SAVA 2
- Target Price
- NA N/A
- SAVA $54.50
- AVG Volume (30 Days)
- NA 433.4K
- SAVA 842.3K
- Earning Date
- NA 09-17-2025
- SAVA 08-07-2025
- Dividend Yield
- NA N/A
- SAVA N/A
- EPS Growth
- NA N/A
- SAVA N/A
- EPS
- NA N/A
- SAVA N/A
- Revenue
- NA $5,561,770.00
- SAVA N/A
- Revenue This Year
- NA N/A
- SAVA N/A
- Revenue Next Year
- NA N/A
- SAVA N/A
- P/E Ratio
- NA N/A
- SAVA N/A
- Revenue Growth
- NA N/A
- SAVA N/A
- 52 Week Low
- NA $2.75
- SAVA $1.15
- 52 Week High
- NA $31.48
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- NA 36.24
- SAVA 50.07
- Support Level
- NA $6.55
- SAVA $2.15
- Resistance Level
- NA $7.54
- SAVA $2.72
- Average True Range (ATR)
- NA 0.89
- SAVA 0.16
- MACD
- NA -0.21
- SAVA -0.02
- Stochastic Oscillator
- NA 3.43
- SAVA 22.79
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.